Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension
- RxCUI
- 832679
- RxNorm name
- Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension
- Display name
- Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension
- Full name
- Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension
- Term type
- SCD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:24
Purple Book Biologic Products#
UNII Substances#
No records found.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| e0b11800-8922-11df-b3d7-0002a5d5c51b | Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/mL Injectable Suspension [PSN] · Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [SCD] | 2 | 14 | These highlights do not include all the information needed to use BIOTHRAX safely and effectively. See full prescribing information for BIOTHRAX. BIOTHRAX ® (Anthrax Vaccine Adsorbed) injectable suspension, for intramuscular or subcutaneous use Initial U.S. Approval: 1970 | 20260123 |
| d4f29180-7c76-40ac-9341-cf62702c4090 | Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/mL Injectable Suspension [PSN] · Bacillus anthracis strain V770-NP1-R antigens 0.1 MG/ML Injectable Suspension [SCD] | 2 | 6 | These highlights do not include all the information needed to use CYFENDUS safely and effectively. See full prescribing information for CYFENDUS . CYFENDUS ® (Anthrax Vaccine Adsorbed, Adjuvanted) injectable suspension, for intramuscular use Initial U.S. Approval: 2023 | 20260225 |